{"article":{"annotation":{"article_id":"uk-mhra-triheptanoin-dojolvi-approval-2026","available_at":"2026-10-31T22:01:36.211578Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"c6944865be6c96dd64d9bafcb42a9c88c69e4e16307b305613c73da46fd5f86e","input_sha256":"1285223b9d6e34a9263589dbd95e81d7eb15556c5ac8a17798a19ef32154fa77","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"GB","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"]}],"geometry":null,"id":"iso3166-1:GB","kind":"country-or-area","labels":{"ar":"المملكة المتحدة لبريطانيا العظمى وآيرلندا الشمالية","en":"United Kingdom of Great Britain and Northern Ireland","es":"Reino Unido de Gran Bretaña e Irlanda del Norte","fr":"Royaume-Uni de Grande-Bretagne et d’Irlande du Nord"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: Healthcare","source_urls":["https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"]}],"method":"controlled-rules-v1","rule_id":"health","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.","Long-chain fatty acid oxidation disorders are rare genetic conditions that disrupt how the body converts long-chain fats into cellular energy, creating severe risks of cardiomyopathy, muscle breakdown and acute hypoglycemia. Triheptanoin, a synthetic odd-carbon medium-chain triglyceride, functions as a direct nutritional energy source to bypass defective enzymatic pathways in the Krebs cycle.","The MHRA noted that conditional authorisation requires ongoing submission of pediatric clinical efficacy and safety data to support full marketing approval. Common reported side effects include gastrointestinal symptoms such as abdominal pain, diarrhoea and nausea. The decision authorizes clinical prescribing under supervised dietary management rather than universal availability across all pharmacy channels."],"sections":[]},"corrections":[],"country":"GB","data":{"blocks":[{"description":{"ar":"نشر إعلان ترخيص التسويق المشروط الرسمي في 30 أكتوبر 2026.","de":"Veröffentlichung der offiziellen Mitteilung zur bedingten Marktzulassung am 30. Oktober 2026.","en":"Publication of the official conditional marketing authorisation announcement on 30 October 2026.","es":"Publicación del anuncio oficial de autorización condicional de comercialización el 30 de octubre de 2026.","fr":"Publication de l’annonce officielle d’autorisation de mise sur le marché conditionnelle le 30 octobre 2026.","pt":"Publicação do anúncio oficial de autorização condicional de introdução no mercado em 30 de outubro de 2026.","tr":"30 Ekim 2026’da resmî şartlı pazarlama izni duyurusunun yayımlanması."},"id":"source-announcement","items":[{"date":"2026-10-30","description":{"ar":"إعلان الموافقة الرسمية في 30 أكتوبر 2026 لعلاج اضطرابات أكسدة الأحماض الدهنية طويلة السلسلة.","de":"Offizielle Zulassung am 30. Oktober 2026 zur Behandlung von Störungen der Fettsäureoxidation bekannt gegeben.","en":"Official approval announced on 30 October 2026 for treating long-chain fatty acid oxidation disorders.","es":"Aprobación oficial anunciada el 30 de octubre de 2026 para el tratamiento de trastornos de oxidación de ácidos grasos de cadena larga.","fr":"Approbation officielle annoncée le 30 octobre 2026 pour le traitement des troubles de l’oxydation des acides gras à chaîne longue.","pt":"Aprovação oficial anunciada em 30 de outubro de 2026 para o tratamento de distúrbios da oxidação de ácidos gordos de cadeia longa.","tr":"Uzun zincirli yağ asidi oksidasyon bozukluklarının tedavisi için 30 Ekim 2026'da resmî onay açıklandı."},"label":{"ar":"وكالة MHRA تصدر ترخيص تسويق مشروط لعقار تريهبتانوين","de":"MHRA erteilt bedingte Marktzulassung für Triheptanoin","en":"MHRA issues conditional marketing authorisation for triheptanoin","es":"La MHRA emite autorización de comercialización condicional para triheptanoína","fr":"La MHRA délivre une autorisation conditionnelle pour la triheptanoïne","pt":"MHRA emite autorização de introdução no mercado condicional para tri-heptanoína","tr":"MHRA, triheptanoin için şartlı pazarlama izni verdi"},"status":"occurred"}],"methodology":{"ar":"يسجل التاريخ يوم نشر المصدر الأولي المشار إليه. وتحدد المادة المؤشرات السريرية والضوابط التنظيمية.","de":"Das Datum bezeichnet die Veröffentlichung der angeführten Primärquelle. Klinische Indikationen und regulatorische Rahmenbedingungen werden im Artikel benannt.","en":"The date records publication of the cited primary source. Clinical indications and regulatory constraints are stated in the article.","es":"La fecha registra la publicación de la fuente primaria citada. El artículo identifica las indicaciones clínicas y las condiciones regulatorias.","fr":"La date correspond à la publication de la source primaire citée. Les indications cliniques et contraintes réglementaires sont précisées dans l’article.","pt":"A data regista a publicação da fonte primária citada. As indicações clínicas e condicionantes regulamentares são identificadas no artigo.","tr":"Tarih, atıf yapılan birincil kaynağın yayımlandığı günü gösterir. Klinik endikasyonlar ve düzenleyici kısıtlar haberde belirtilmiştir."},"sourceUrls":["https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"],"title":{"ar":"نشر المصدر","de":"Quellenveröffentlichung","en":"Source publication","es":"Publicación de la fuente","fr":"Publication de la source","pt":"Publicação da fonte","tr":"Kaynak yayını"},"type":"events","updatedAt":"2026-11-01T00:43:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026/data/source-announcement?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026/data/source-announcement?lang=en&format=json"},"id":"source-announcement"}],"data_types":["events"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-e7c50bae-6da6-56a7-bd4c-7b41c7c11b9d","event_period":"2026-10-30","event_period_basis":"event-or-reference-period","id":"uk-mhra-triheptanoin-dojolvi-approval-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-11-01T00:43:00Z","publication_basis":"publication-record","published_at":"2026-10-31T22:01:30+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"uk-mhra-triheptanoin-dojolvi-approval-2026","sources":[{"checkedAt":"2026-11-01","name":"Medicines and Healthcare products Regulatory Agency, United Kingdom","publishedAt":"2026-10-30","url":"https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"}],"summary":"The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.","text":"The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.\n\nThe UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.\n\nLong-chain fatty acid oxidation disorders are rare genetic conditions that disrupt how the body converts long-chain fats into cellular energy, creating severe risks of cardiomyopathy, muscle breakdown and acute hypoglycemia. Triheptanoin, a synthetic odd-carbon medium-chain triglyceride, functions as a direct nutritional energy source to bypass defective enzymatic pathways in the Krebs cycle.\n\nThe MHRA noted that conditional authorisation requires ongoing submission of pediatric clinical efficacy and safety data to support full marketing approval. Common reported side effects include gastrointestinal symptoms such as abdominal pain, diarrhoea and nausea. The decision authorizes clinical prescribing under supervised dietary management rather than universal availability across all pharmacy channels.","title":"UK MHRA grants conditional approval for triheptanoin in rare metabolic disorders","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/uk-mhra-triheptanoin-dojolvi-approval-2026"}],"url":"https://newsverum.com/en/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},"version":"1"}
